Hostname: page-component-f554764f5-fnl2l Total loading time: 0 Render date: 2025-04-21T00:09:44.818Z Has data issue: false hasContentIssue false

370 Improving risk stratification in kidney transplant outcomes by modeling antigen processing to inform prediction of T-cell epitopes derived from mismatched HLA proteins

Published online by Cambridge University Press:  11 April 2025

Alyssa Paynter
Affiliation:
Tulane University School of Medicine
Jiarui Li
Affiliation:
Department of Computer Science, School of Engineering, Tulane University, New Orleans, LA 70118
Marco Carbullido
Affiliation:
Department of Computer Science, School of Engineering, Tulane University, New Orleans, LA 70118
Ramgopal Mettu
Affiliation:
Department of Computer Science, School of Engineering, Tulane University, New Orleans, LA 70118
Samuel Landry
Affiliation:
Department of Biochemistry and Molecular Biology, School of Medicine, Tulane University, New Orleans, LA 70112
Loren Gragert
Affiliation:
Tulane Center for Biomedical Informatics and Genomics, Deming Department of Medicine, School of Medicine, Tulane University, New Orleans, LA 70112
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Objectives/Goals: We aim to enhance risk prediction in kidney transplantation outcomes by improving models of peptide antigen presentation of mismatched HLA molecules. HLA-derived peptides presented by HLA Class II to T-cells can activate an immune response, ultimately leading to graft failure. We aim to improve peptide prediction by modeling antigen processing. Methods/Study Population: T-cell epitope models for HLA mismatching struggle to predict which peptides are presented because antigen processing by proteases is not well modeled. We model antigen processing of HLA Class II proteins using 3D HLA structures (crystallography data) to create an HLA-specific antigen processing likelihood (APL) model. APL uses conformational stability measurements such as b-factor, COREX, solvent accessible surface area, and sequence entropy to predict cleavage sites from proteolysis. We will integrate APL into a T-cell epitope prediction tool for HLA-derived peptides based on donor and recipient HLA genotypes. Finally, we will associate the risk of graft failure with counts of these peptides derived from APL-integrated prediction models using a historical kidney transplant cohort from 2000 to 2023. Results/Anticipated Results: We expect that applying APL could reduce false-positive peptide binders influencing risk prediction scores. We anticipate improved peptide prediction accuracy compared to existing tools such as NetMHCIIPan, which assumes all possible peptides are equally likely to emerge from antigen processing. NetMHCIIPan is currently used by PIRCHE-II HLA mismatch risk algorithm. We expect that merging antigen processing (APL) and peptide-binding (NetMHCIIPan) models into a unified model would enhance risk stratification for graft failure. Current risk stratification still leads to poor outcomes post-transplant, especially for minority population groups. Our model can identify an alternative pool of well-matched donors and has the potential to improve equity for non-White minority candidates. Discussion/Significance of Impact: Improving the understanding of how HLA matching contributes to kidney transplant outcomes can better stratify risks for kidney transplant recipients, enable personalized treatment, and ultimately improve outcomes for those undergoing kidney transplantation to treat renal diseases.

Type
Informatics, AI and Data Science
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2025. The Association for Clinical and Translational Science